Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.43 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | GSK3A | P49840 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2302565 | 0.94 | CHRM2 (0.46) | L3MBTL1CHRM2CHRM4CHRM5OPRK1 | |
| SCHEMBL3082052 | 0.82 | CHRM2 (0.42) | KMT2AL3MBTL1LMNACHRM2CHRM4 | |
| SCHEMBL12902953 | 0.82 | KMT2A (0.51) | KMT2AL3MBTL1LMNACHRM2CHRM4 | |
| SCHEMBL911191 | 0.82 | KMT2A (0.51) | KMT2AL3MBTL1LMNACHRM2CHRM4 | |
| SCHEMBL15425873 | 0.82 | KMT2A (0.51) | KMT2AL3MBTL1LMNACHRM2CHRM4 | |
| Bromide SCHEMBL9957539 | 0.80 | KMT2A (0.50) | KMT2AL3MBTL1LMNACHRM2CHRM4 | |
| Hydrochloric Acid SCHEMBL18063 | 0.80 | CHRM2 (0.53) | KMT2AL3MBTL1LMNACHRM2CHRM4 | |
| SCHEMBL12564502 | 0.80 | CHRM2 (0.56) | KMT2AL3MBTL1LMNACHRM2CHRM4 | |
| SCHEMBL4870895 | 0.78 | CHRM2 (0.60) | KMT2AL3MBTL1LMNACHRM2CHRM4 | |
| SCHEMBL5728905 | 0.76 | CHRM2 (0.58) | KMT2AL3MBTL1LMNACHRM2CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8609659-B2 | Substituted 3,8-diazabicyclo[3.2.1]octane compounds | NEUROSCIENZE PHARMANESS S.C.A.R.L. (IT) | 2013-12-17 | — | — | US | disclosed |
| US-8399457-B2 | Pharmaceutical compounds | NEUROSCIENZE PHARMANESS S.C. A.R.L. (IT) | 2013-03-19 | — | — | US | disclosed |
| US-8399457-B2 | Pharmaceutical compounds | NEUROSCIENZE PHARMANESS S.C. A.R.L. (IT) | 2013-03-19 | — | — | US | disclosed |
| EP-2149575-B1 | Diazabicyclic compounds as opioid receptor agonists | NEUROSCIENZE PHARMANESS S C A R L (IT) | 2012-10-24 | — | — | EP | disclosed |
| EP-2338889-B1 | Diazacyclic compounds having affinity for opioid receptors | NEUROSCIENZE PHARMANESS S C A R L (IT) | 2012-08-29 | — | — | EP | disclosed |
| EP-2338889-A1 | Diazacyclic compounds having affinity for opioid receptors | Neuroscienze Pharmaness S.C. A R.L. (IT) | 2011-06-29 | — | — | EP | disclosed |
| US-20110152238-A1 | PHARMACEUTICAL COMPOUNDS | NEUROSCIENZE PHARMANESS S.C. A.R.L. (IT) | 2011-06-23 | — | — | US | disclosed |
| US-20110152238-A1 | PHARMACEUTICAL COMPOUNDS | NEUROSCIENZE PHARMANESS S.C. A.R.L. (IT) | 2011-06-23 | — | — | US | disclosed |
| US-20100029622-A1 | MICROEMULSIONS | NEUROSCIENZE PHARMANESS S.C.A.R.L. (IT) | 2010-02-04 | — | — | US | disclosed |
| US-20100029622-A1 | MICROEMULSIONS | NEUROSCIENZE PHARMANESS S.C.A.R.L. (IT) | 2010-02-04 | — | — | US | disclosed |
| US-20100028257-A1 | PHARMACEUTICAL COMPOUNDS | NEUROSCIENZE PHARMANESS S.C. A.R.L. (IT) | 2010-02-04 | — | — | US | disclosed |
| US-20100028257-A1 | PHARMACEUTICAL COMPOUNDS | NEUROSCIENZE PHARMANESS S.C. A.R.L. (IT) | 2010-02-04 | — | — | US | disclosed |
| EP-2149575-A1 | Diazabicyclic compounds as opioid receptor agonists | Neuroscienze Pharmaness S.C. A R.L. (IT) | 2010-02-03 | — | — | EP | disclosed |
| EP-2149370-A1 | Diazabicyclic compounds and microemulsions thereof | Neuroscienze Pharmaness S.C. A R.L. (IT) | 2010-02-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100028257-A1 | PHARMACEUTICAL COMPOUNDS | OPRD1, OPRK1, OPRM1 | KMT2A 2488/4885L3MBTL1 4557/4885LMNA 4122/4885 |
| US-20110152238-A1 | PHARMACEUTICAL COMPOUNDS | OPRD1, OPRK1, OPRM1 | KMT2A 3835/4885L3MBTL1 2576/4885LMNA 3155/4885 |
| US-20100029622-A1 | MICROEMULSIONS | LIPA, APOB, LIPC | KMT2A 3282/4885L3MBTL1 4704/4885LMNA 1557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.